Skip to main content
. 2012 May 1;14(3):500–509. doi: 10.1208/s12248-012-9363-4

Fig. 5.

Fig. 5

Response to isoform-specific treatment in tumors that preferentially secrete various VEGF isoform(s). The fold-change in free VEGF concentration in isoform-specific tumors following targeting all isoforms simultaneously (light gray), VEGF121 (dark gray), or VEGF165 (black). From top to bottom: normal tissue (subscript N), blood (subscript B), and tumor (subscript T)